Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis.

Publication

Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis.

Journal Paper/Review - Jun 30, 2023

Alamo Beatriz Sanchez, Moi Laura, Bajema Ingeborg M, Faurschou Mikkel, Flossmann Oliver, Hauser Thomas, Hruskova Zdenka, Jayne David R.W., Luqmani Raashid A, Mahr Alfred, Åkesson Anna, Westman Kerstin, EUVAS

Citation

Alamo B, Moi L, Bajema I, Faurschou M, Flossmann O, Hauser T, Hruskova Z, Jayne D, Luqmani R, Mahr A, Åkesson A, Westman K, EUVAS. Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis. Nephrol Dial Transplant 2023; 38:1655-1665.

Type

Journal Paper/Review (English)

Journal

Nephrol Dial Transplant 2023; 38

Publication Date

Jun 30, 2023

Issn Electronic

1460-2385

Pages

1655-1665

Brief description/objective

Despite newer treatments with immunosuppressive agents, there still exists a considerable morbidity and mortality risk among patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Since 1994 the European Vasculitis Society (EUVAS) has aimed for an improved outcome for patients with AAV, conducting several prospective randomized controlled trials (RCTs). The aim for the present study was to further evaluate the long-term survival of patients with AAV included in seven RCTs conducted by the EUVAS as well as to identify potential prognostic factors.